Collaboration Hub

Collaboration

Venus Remedies continually invites, explore collaboration and partnership with the single most objective to alleviate human sufferings and make better tomorrow. Thus, Venus Remedies invests in opportunities through collaboration and partnerships across the globe in multi-facet  of activities for fulfilling pharmaceutical operations. Venus Remedies  has historically been in constant touch with best of the research  Institute & labs, Universities, NGOs, Government Bodies, business  houses and eminent experts in a host of activities that include  technology development & licensing, transfer of technology,  marketing & promotion, training and skill developments.

INFEX Therapeutics (UK)

VMRC formalised an in-licensing and co-development agreement with INFEX Therapeutics, a UK-based biotechnology company, for MET-X, a novel β-lactamase inhibitor.

This collaboration brings a globally promising AMR asset into VMRC’s pipeline and exemplifies the organisation’s commitment to acquiring high-value, resistance-breaking molecules. Through this partnership, VMRC gains access to cutting-edge science and development data, enabling rapid advancement of MET-X through pre-clinical and clinical phases. The collaboration supports VMRC’s long-term strategy of building a differentiated AMR portfolio. It contributes to the global push for new-generation β-lactamase inhibitors to combat extendedspectrum and carbapenem-resistant pathogens.

Adjutec Pharma (Norway)

In another key alliance, VMRC initiated joint pre-clinical studies and testing for APC-148 in collaboration with Adjutec Pharma, a Norway-based biopharmaceutical company.

APC-148 is a novel inhibitor with significant potential in combating antimicrobial resistance by targeting unique enzymatic pathways. Adjutec Research Collaboration has enabled both organisations to pool scientific expertise and research infrastructure to accelerate the development of APC-148. By working closely with Adjutec Pharma, VMRC can diversify its AMR innovation pipeline and explore novel mechanisms of action that can address unmet clinical needs in resistant bacterial infections.

Veeda Clinical Research (India)

VMRC also partnered with Veeda Clinical Research, one of India’s leading clinical research organisations, to execute a complex Phase 1 trial of VRP-034.

This trial included advanced features such as renal safety assessments and adaptive study design elements to ensure comprehensive evaluation of the molecule’s safety profile. Veeda’s operational excellence in early-phase trials helped streamline study implementation, while VMRC provided scientific and regulatory oversight. The collaboration not only accelerated the clinical readiness of VRP-034 but also established a robust model for future clinical trial partnerships. This joint effort highlights VMRC’s commitment to rigorous, patient-centric clinical development that is aligned with global standards.

AMR Vivli Onboarding

VMRC’s commitment to global scientific collaboration and open-access data sharing was recognised when it was formally onboarded to the Vivli AMR Surveillance and Register initiative.

Participation in this prestigious international platform highlights VMRC’s expanding global footprint and underscores its contribution to the collective fight against antimicrobial resistance. Being part of the Vivli network enables VMRC to engage with a diverse community of stakeholders committed to transparency and innovation in AMR research.

Existing and Past Collaborations

We owe our existence and growth to Research and Development. With strong commitment, VMRC has metamorphosed itself into the leaders providing  innovative solutions to the unmet medical needs in the field of  Anti-Microbial Resistance (AMR), Oncology, Wound care, Pain management.  Our GLP accredited labs are committed to bringing to the world novel  breakthroughs that cater to critical care and super specialty segment.  We have the right blend of the spectrum, vision, talent and capabilities that we enabling us to actualize our goals.